Cocaine and the club drugs

International Anesthesiology Clinics

Volumn 49, Issue 1, 2011, Pages 79-101

  Demaria Jr , Samuel ^a   Weinkauf, Julia L ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; AMPHETAMINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORIC ACID; CAFFEINE; COCAINE; DESFLURANE; DEXMEDETOMIDINE; DIAMORPHINE; DIAZEPAM; FLUNITRAZEPAM; GLUCOSE; GLYCERYL TRINITRATE; ISOFLURANE; KETAMINE; LACTOSE; MAGNESIUM SULFATE; MANNITOL; MIDAZOLAM; PHENTOLAMINE; PROCAINE; PROPRANOLOL; QUININE; RECREATIONAL DRUG; SALICYLAMIDE; SEVOFLURANE; TALC; VERAPAMIL;

ANESTHESIA; ANESTHESIST; ARTICLE; CARDIOVASCULAR DISEASE; COCAINE DEPENDENCE; CORONARY ARTERY SPASM; DRUG ABUSE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG DISEASE; NEUROLOGIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; SUBSTANCE ABUSE;

ANESTHESIOLOGY; COCAINE; COCAINE-RELATED DISORDERS; FLUNITRAZEPAM; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SODIUM OXYBATE; STREET DRUGS;

EID: 78751629537     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e3181ffc0cb     Document Type: Article

References (83)

1. Van Dyke C, Byck R. Cocaine. Sci Am. 1982;246:128-141.
2. Schoenberg BS. Coke's the one: the centennial of the "ideal brain tonic" that became a symbol of America. South Med J. 1988;81:69-74.
3. Pendergrast M. For God, Country, and Coca-Cola. New York: Charles Scribner's Sons; 1993; 32-33, 90-91, 355-356.
4. US Department of Health and Human Services. National Survey on Drug Use and Health. Washington DC: US Department of Health and Human Services; 2008. [Figures 2.1 2.6]
5. Brookoff D, Campbell EA, Shaw LM. The underreporting of cocaine-related trauma: drug abuse warning network reports versus hospital toxicology tests. Am J Public Health. 1993;83:369-371.
6. Foltin RW, Fischman MW. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther. 1991;257:247-261.
7. Moliterno DJ, Lange RA, Gerard RD, et al. Influence ofintranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am J Med. 1994;96:492-496.
8. Devlin RJ, Henry JA. Clinical review: major consequences of illicit drug consumption. Crit Care. 2008;12:202. doi: 10.1186/cc6166.
9. Heesch CM, Negus BH, Steiner M, et al. Effects of in vivo cocaine administration on human platelet aggregation. Am J Cardiol. 1996;78:237-239.
10. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345:351-358.
11. Nademanee K, Gorelick DA, Josephson MA, et al. Myocardial ischemia during cocaine withdrawal. Ann Intern Med. 1989;111:876-880.
12. Lucena J, Blanco M, Jurado C, et al. Cocaine-related sudden death: a prospective investigation in south-west Spain. Eur HeartJ. 2010;31:318-329.
13. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements ("crack dancing"). Neurology. 1994;44:751-752.
14. Gotway MB, Marder SR, Hanks DK, et al. Thoracic complications of illicit drug use: an organ system approach. Radiographics. 2002;22:S119-S135.
15. Abramson DL, Gertler JP, Lewis T, et al. Crack-related perforated gastropyloric ulcer. J Clin Gastroenterol. 1991;13:17-19.
16. Mochizuki Y, Zhang M, Golestaneh L, et al. Acute aortic thrombosis and renal infarction in acute cocaine intoxication: a case report and review of literature. Clin Nephrol. 2003;60:130-133.
17. Feinstein L, Schmidt K. Cocaine users present unique anesthetic challenges: part 2. Anesthesiol News. 2010;36:30-31.
18. Hill GE, Ogunnaike BO,Johnson ER. General anaesthesia for the cocaine abusing patient. Is it safe? Br JAnaesth. 2006;97:654-657.
19. Stephens BG, Jentzen JM, Karch S, et al. NationalAssociation ofMedical Examiners position paper on the certification of cocaine-related deaths. Am J Forensic Med Pathol. 2004;25:11-13.
20. Menon DV, Wang Z, Fadel PJ, et al. Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol. 2007;50:626-633.
21. Hernandez M, Birnbach DJ, Van Zundert AAJ. Anesthetic management of the illicit-substance-using patient. Curr Opin Anaesthesiol. 2005;18:315-324.
22. Himmel HM. Mechanisms involved in cardiac sensitization by volatile anesthetics: general applicability to halogenated hydrocarbons? Crit Rev Toxicol. 2008;38:773-803.
23. Hoffman RS. Cocaine and beta-blockers: should the controversy continue? Ann Emerg Med. 2008;51:127-129.
24. McCordJ,Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117:1897-1907.
25. Kuczkowski KM. The cocaine abusing parturient: a review of anesthetic considera-tions. CanJAnaesth. 2004;51:145-154.
26. European Monitoring Centre for Drugs and Drug addiction. The state of the drugs problem in the European Union and Norway: Annual report 2007.
27. US Department of Heath and Human Services. National Survey on Drug Use and Health. Washington DC: US Department of Health and Human Services; 2005:55-75.
28. National Institute on Drug Abuse. The Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings 2001. Ann Arbor, Mich: University of Michigan Institute for Social Research 2002, 101-123.
29. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21:1486-1513.
30. Suarez RV, Riemersma R. "Ecstasy" and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339-341.
31. Shulgin AT The background and chemistry of MDMA. J Psychoactive Drugs. 1986;18:291-304.
32. Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs. 1998;30:371-379.
33. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319-327.
34. Wolff K, Hay AWM, Sherlock K, et al. Contents of "ecstasy." Lancet. 1995;346: 1100-1101.
35. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5: 79-86.
36. Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharma-cokinetic interactions. Psychosomatics. 2004;45:84-87.
37. Ferigolo M, Machado AGS, Oliveira NB, et al. Ecstasy intoxication: the toxicological basis for treatment. Rev Hosp Clin Fac Med São Paulo. 2003;58:332-341.
38. Cami J, Farre M, Mas M. Human pharmacology of 3,4-methylenedioxymetham- phetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455-466.
39. Peroutka SJ. Incidence ofrecreational use of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. N Engl J Med. 1987;317: 1542-1543.
40. Cohen RS. Subjective reports on the effects of the MDMA ("ecstasy") experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1137-1145.
41. O'Cain PA, Hletko SB, Ogden BA, et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav. 2000;70:141-148.
42. Walsh T, Carmichale R, Chestnut J. A hyperthermic reaction to ecstasy. BrJHosp Med. 1994;51:476.
43. Gill JR, HayesJA, de Souza IS, et al. Ecstasy (MDMA) deaths in New York city: a case series and review of the literature. J Forensic Sci. 2002;47:121-126.
44. Logan ASC, Stickle B, O'Keefe N, et al. Survival following "ecstasy" ingestion with a peaktemperature of 42°C. Anaesthesia. 1993;48:1017-1018
45. Hall AP. "Ecstasy" and the anaesthetist. Br J Anaesth. 1997;79:697-698.
46. Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with "ecstasy" and "Eve" misuse. J Clin Pathol. 1996;49:149-153.
47. Schmidt CJ, Black CK, Abbate GM, et al. MDMAinduced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85-90.
48. Nimmo SM, Kennedy BW, Tullett WM, et al. Drug-induced hyperthermia. Anaesthesia. 1993;48:892-895.
49. Benowitz NL. Amphetamines. In: Olson KR, ed. Poisoning and Drug Overdose. 3rd ed. Stamford, CT: Appleton and Lange; 1999:68-70.
50. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.
51. Brody S, Krause C, Veit R, et al. Cardiovascular autonomic dysregulation in users of MDMA ("ecstasy"). Psychopharmacology. 1998;136:390-393.
52. Kessel B. Hyponatraemia after ingestion of "ecstasy." BMJ. 1994;308:414.
53. Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA) [letter]. Lancet. 1996;347:1052.
54. Henry JA, Fallon JK, Kicman AT. Low-dose MDMA ("ecstasy") induces vasopressin secretion. [letter]. Lancet. 1998;351:1784.
55. Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229-233.
56. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxi-city in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129-133.
57. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449-454.
58. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107:1-10.
59. Klein M, Kramer F. Rave drugs: pharmacological considerations. AANA J. 2004; 72:61-67.
60. Reneman L, Habraken JB, Majoie CB, et al. MDMA ("ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol. 2000; 21:1001-1007.
61. Richards JR. Rhabdomyolisis and drugs abuse.JEmergMed. 2000;19:51-56.
62. Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686-687.
63. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. DrugAlcohol Depend. 2001;63:1-22.
64. Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of "club drugs." Subst Use Misuse. 2005;40:1189-1201.
65. Okun M, Bartfield RB, Doering PL. GHB toxicity: what you need to know. Emerg Med. 2000:10-23.
66. Knudsen K, Greter J, Verdicchio M, et al. A severe outburst of GHB poisonings (gammahydroxybutyrate, gamma-hydroxybutyric acid) on the West Coast of Sweden. Mortality numbers ahead of heroin. Clin Toxicol. 2006;44:637-638.
67. Halkitis PN, Palamar JJ. GHB use among gay and bisexual men. Addict Behav. 2006;31:2135-2139.
68. Tunnicliff G. Sites of action of gamma-hydroxybutyrate-a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35:581-590.
69. Hedou G, Chasserot-Golaz S, Kemmel V, et al. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol. 2000;426:549-560.
70. Graeme KA. New drugs of abuse. Emerg Med Clin North Am. 2000;18:625-636.
71. Galloway GP, Frederick SL, Staggers F Jr. Physical dependence on sodium oxybate. Lancet. 1994;343:57.
72. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23:151-156.
73. McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolac-tone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001;33:143-149.
74. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37:147-153.
75. Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7:278-281.
76. Berti M, Baciarello M, Troglio R, et al. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets. 2009;10:707-715.
77. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30:563-569.
78. Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs. 2001;33:151-158.
79. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186-1193.
80. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anesth. 1989;36:186-197.
81. Weiner AL, Viera L, McKay CA, et al. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447-451.
82. Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care. 2002;30:382-384.
83. Ricaurtie GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet. 2005;365:2137-2145.